{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Xencor, Inc."},"Symbol":{"label":"Symbol","value":"XNCR"},"Address":{"label":"Address","value":"111 WEST LEMON AVENUE, MONROVIA, California, 91016, United States"},"Phone":{"label":"Phone","value":"+1 626 305-5900"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates."},"CompanyUrl":{"label":"Company Url","value":"https://www.xencor.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Bassil I. Dahiyat","title":"President, Chief Executive Officer & Director"},{"name":"John R. Desjarlais","title":"Chief Scientific Officer & Executive VP-Research"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}